Pioneering technique reveals structure of Parkinson's disease protein in action
SABER is a nanotechnology employing customized DNA templates that can attach to molecules of interest. Each DNA template also has targets for adding fluorescent probes, which can be designed to have a branching pattern to accommodate more fluorescent probes, thereby making it easier to detect rare molecules. In the first demonstration of SABER technology, Yin and colleagues targeted DNA and RNA sequences in mouse retina and also visualized 17 different target regions simultaneously on the human X-chromosome. This is a significant improvement over the conventional method, known as FISH (fluorescence in situ hybridization), which had a hard time detecting rare sequences, especially in thick tissue, and was limited to one fluorescent probe.
To use SABER to detect proteins, Yin and colleagues attached short DNA handles to antibodies. The antibodies bind specifically to proteins, then the SABER process can add DNA sequences in a branching pattern to add fluorescent molecules. They named the technique immuno-SABER. Unlike standard immuno-florescence, in which only five proteins can typically be labelled in the same sample, by coupling immuno-SABER to a DNA exchange method, they labeled ten proteins in the same retina sample.
Because of its speed, low cost, and ability to detect many low-abundance molecules in the same sample, SABER offers the possibility of high-throughput screening, which could advance basic biology, biomarker discovery, and clinical diagnostics, Yin says. And someday, PengYin says:
SABER could be useful for matching patients with optimal treatments based on the spatial pattern of protein markers. For example, for cancer, the tumor microenvironment can be characterized by the spatial expression pattern of the protein markers, which could inform immunotherapy treatment." Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology